A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma.

Trial Profile

A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Oxaliplatin (Primary) ; Gemcitabine; Paclitaxel
  • Indications Germ cell and embryonal neoplasms; Testicular cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 25 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 25 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top